- Home
- PB vs LEGN Comparison
PB vs LEGN Comparison
Compare PB & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PB
- LEGN
- Stock Information
- Founded
- PB 1983
- LEGN 2014
- Country
- PB United States
- LEGN United States
- Employees
- PB N/A
- LEGN N/A
- Industry
- PB Major Banks
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- PB Finance
- LEGN Health Care
- Exchange
- PB Nasdaq
- LEGN Nasdaq
- Market Cap
- PB 6.4B
- LEGN 5.4B
- IPO Year
- PB 1998
- LEGN 2020
- Fundamental
- Price
- PB $67.99
- LEGN $36.08
- Analyst Decision
- PB Buy
- LEGN Strong Buy
- Analyst Count
- PB 16
- LEGN 12
- Target Price
- PB $83.53
- LEGN $73.36
- AVG Volume (30 Days)
- PB 990.8K
- LEGN 1.0M
- Earning Date
- PB 10-22-2025
- LEGN 08-11-2025
- Dividend Yield
- PB 3.41%
- LEGN N/A
- EPS Growth
- PB 20.55
- LEGN N/A
- EPS
- PB 5.49
- LEGN N/A
- Revenue
- PB $1,227,788,000.00
- LEGN $796,838,000.00
- Revenue This Year
- PB $10.46
- LEGN $70.75
- Revenue Next Year
- PB $14.54
- LEGN $52.47
- P/E Ratio
- PB $12.40
- LEGN N/A
- Revenue Growth
- PB 9.17
- LEGN 74.75
- 52 Week Low
- PB $61.57
- LEGN $27.34
- 52 Week High
- PB $86.76
- LEGN $57.54
- Technical
- Relative Strength Index (RSI)
- PB 45.68
- LEGN 48.36
- Support Level
- PB $68.11
- LEGN $34.14
- Resistance Level
- PB $69.65
- LEGN $36.17
- Average True Range (ATR)
- PB 1.14
- LEGN 1.08
- MACD
- PB 0.11
- LEGN 0.07
- Stochastic Oscillator
- PB 37.61
- LEGN 48.67
About PB Prosperity Bancshares Inc.
Prosperity Bancshares Inc provides retail and commercial banking services to individuals and small to midsize businesses. It provides a wide array of financial products and services to businesses and consumers throughout Texas and Oklahoma. The group provides Personal, Business, Mortgage, and Banking Services.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.